Zika Virus: Immunity and Vaccine Development

Cell

Volumn 167, Issue 3, 2016, Pages 625-631

  Pierson, Theodore C ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; EPITOPE; INACTIVATED VACCINE; INTERFERON; LIVE VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PROTEINASE; RNA VACCINE; STRUCTURAL PROTEIN; VIRUS ANTIGEN; VIRUS FUSION PROTEIN; VIRUS VECTOR; ZIKA VIRUS VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENGUE VIRUS; HUMAN; IMMUNITY; INFECTION PREVENTION; INNATE IMMUNITY; MICROCEPHALY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEROLOGY; VERTICAL TRANSMISSION; VIRION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; ZIKA FEVER; ZIKA VIRUS; BLOOD; IMMUNOLOGY; T LYMPHOCYTE; TRANSMISSION; ZIKA VIRUS INFECTION;

ANTIBODIES, VIRAL; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTES; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84994059378     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.09.020     Document Type: Review

References (85)

1. Abbink, P., Larocca, R.A., De La Barrera, R.A., Bricault, C.A., Moseley, E.T., Boyd, M., Kirilova, M., Li, Z., Ng'ang’a, D., Nanayakkara, O., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353 (2016), 1129–1132.
2. Alera, M.T., Hermann, L., Tac-An, I.A., Klungthong, C., Rutvisuttinunt, W., Manasatienkij, W., Villa, D., Thaisomboonsuk, B., Velasco, J.M., Chinnawirotpisan, P., et al. Zika virus infection, Philippines, 2012. Emerg. Infect. Dis. 21 (2015), 722–724.
3. Allison, S.L., Stadler, K., Mandl, C.W., Kunz, C., Heinz, F.X., Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69 (1995), 5816–5820.
4. Aubry, M., Finke, J., Teissier, A., Roche, C., Broult, J., Paulous, S., Desprès, P., Cao-Lormeau, V.M., Musso, D., Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013. Int. J. Infect. Dis. 41 (2015), 11–12.
5. Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.M., Haouz, A., et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536 (2016), 48–53.
6. Bayer, A., Lennemann, N.J., Ouyang, Y., Bramley, J.C., Morosky, S., Marques, E.T. Jr., Cherry, S., Sadovsky, Y., Coyne, C.B., Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection. Cell Host Microbe 19 (2016), 705–712.
7. Beck, A.S., Barrett, A.D., Current status and future prospects of yellow fever vaccines. Expert Rev. Vaccines 14 (2015), 1479–1492.
8. Beckett, C.G., Tjaden, J., Burgess, T., Danko, J.R., Tamminga, C., Simmons, M., Wu, S.J., Sun, P., Kochel, T., Raviprakash, K., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29 (2011), 960–968.
9. Brooks, J.T., Friedman, A., Kachur, R.E., LaFlam, M., Peters, P.J., Jamieson, D.J., Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus - United States, July 2016. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 745–747.
10. Bukowski, J.F., Kurane, I., Lai, C.J., Bray, M., Falgout, B., Ennis, F.A., Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J. Virol. 63 (1989), 5086–5091.
11. Campos, G.S., Bandeira, A.C., Sardi, S.I., Zika Virus Outbreak, Bahia, Brazil. Emerg. Infect. Dis. 21 (2015), 1885–1886.
12. Cao-Lormeau, V.M., Roche, C., Teissier, A., Robin, E., Berry, A.L., Mallet, H.P., Sall, A.A., Musso, D., Zika virus, French polynesia, South pacific, 2013. Emerg. Infect. Dis. 20 (2014), 1085–1086.
13. Cao-Lormeau, V.M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387 (2016), 1531–1539.
14. Chen, Y., Maguire, T., Hileman, R.E., Fromm, J.R., Esko, J.D., Linhardt, R.J., Marks, R.M., Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3 (1997), 866–871.
15. Crill, W.D., Chang, G.J., Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78 (2004), 13975–13986.
16. D'Ortenzio, E., Matheron, S., Yazdanpanah, Y., de Lamballerie, X., Hubert, B., Piorkowski, G., Maquart, M., Descamps, D., Damond, F., Leparc-Goffart, I., Evidence of Sexual Transmission of Zika Virus. N. Engl. J. Med. 374 (2016), 2195–2198.
17. Dai, L., Song, J., Lu, X., Deng, Y.Q., Musyoki, A.M., Cheng, H., Zhang, Y., Yuan, Y., Song, H., Haywood, J., et al. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host Microbe 19 (2016), 696–704.
18. Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N.T., Duangchinda, T., et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16 (2015), 170–177.
19. Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., Sakuntabhai, A., Cao-Lormeau, V.M., Malasit, P., Rey, F.A., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17 (2016), 1102–1108.
20. Dick, G.W., Kitchen, S.F., Haddow, A.J., Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46 (1952), 509–520.
21. Dowd, K.A., Pierson, T.C., Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411 (2011), 306–315.
22. Dowd, K.A., DeMaso, C.R., Pelc, R.S., Speer, S.D., Smith, A.R., Goo, L., Platt, D.J., Mascola, J.R., Graham, B.S., Mulligan, M.J., et al. Broadly neutralizing activity of zika virus-immune sera identifies a single viral serotype. Cell Rep. 16 (2016), 1485–1491.
23. Duffy, M.R., Chen, T.H., Hancock, W.T., Powers, A.M., Kool, J.L., Lanciotti, R.S., Pretrick, M., Marfel, M., Holzbauer, S., Dubray, C., et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 360 (2009), 2536–2543.
24. Durbin, A.P., Whitehead, S.S., Dengue vaccine candidates in development. Curr. Top. Microbiol. Immunol. 338 (2010), 129–143.
25. Fagbami, A.H., Halstead, S.B., Marchette, N.J., Larsen, K., Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios 49 (1987), 49–55.
26. Fibriansah, G., Tan, J.L., Smith, S.A., de Alwis, R., Ng, T.S., Kostyuchenko, V.A., Jadi, R.S., Kukkaro, P., de Silva, A.M., Crowe, J.E., Lok, S.M., A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun., 6, 2015, 6341.
27. Grant, A., Ponia, S.S., Tripathi, S., Balasubramaniam, V., Miorin, L., Sourisseau, M., Schwarz, M.C., Sánchez-Seco, M.P., Evans, M.J., Best, S.M., García-Sastre, A., Zika virus targets human stat2 to inhibit type i interferon signaling. Cell Host Microbe 19 (2016), 882–890.
28. Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14 (2016), 45–54.
29. Hadinegoro, S.R., Arredondo-García, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Dietze, R., Muhammad Ismail, H.I., Reynales, H., Limkittikul, K., Rivera-Medina, D.M., et al., CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373 (2015), 1195–1206.
30. Halstead, S.B., Dengue. Lancet 370 (2007), 1644–1652.
31. Halstead, S.B., Thomas, S.J., New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 10 (2011), 355–364.
32. Halstead, S.B., Mahalingam, S., Marovich, M.A., Ubol, S., Mosser, D.M., Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10 (2010), 712–722.
33. Hamel, R., Dejarnac, O., Wichit, S., Ekchariyawat, P., Neyret, A., Luplertlop, N., Perera-Lecoin, M., Surasombatpattana, P., Talignani, L., Thomas, F., et al. Biology of zika virus infection in human skin cells. J. Virol. 89 (2015), 8880–8896.
34. Heang, V., Yasuda, C.Y., Sovann, L., Haddow, A.D., Travassos da Rosa, A.P., Tesh, R.B., Kasper, M.R., Zika virus infection, Cambodia, 2010. Emerg. Infect. Dis. 18 (2012), 349–351.
35. Heinz, F.X., Stiasny, K., Flaviviruses and their antigenic structure. J. Clin. Virol. 55 (2012), 289–295.
36. Jampol, L.M., Goldstein, D.A., Zika virus infection and the eye. JAMA Ophthalmol., 2016, 10.1001/jamaophthalmol.2016.0284 Published online February 9, 2016.
37. Jarmer, J., Zlatkovic, J., Tsouchnikas, G., Vratskikh, O., Strauß, J., Aberle, J.H., Chmelik, V., Kundi, M., Stiasny, K., Heinz, F.X., Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J. Virol. 88 (2014), 13845–13857.
38. Johansson, M.A., Mier-y-Teran-Romero, L., Reefhuis, J., Gilboa, S.M., Hills, S.L., Zika and the Risk of Microcephaly. N. Engl. J. Med. 375 (2016), 1–4.
39. Kaufmann, B., Vogt, M.R., Goudsmit, J., Holdaway, H.A., Aksyuk, A.A., Chipman, P.R., Kuhn, R.J., Diamond, M.S., Rossmann, M.G., Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. USA 107 (2010), 18950–18955.
40. Kirkpatrick, B.D., Whitehead, S.S., Pierce, K.K., Tibery, C.M., Grier, P.L., Hynes, N.A., Larsson, C.J., Sabundayo, B.P., Talaat, K.R., Janiak, A., et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci. Transl. Med., 8, 2016, 330ra36.
41. Kleber de Oliveira, W., Cortez-Escalante, J., De Oliveira, W.T., do Carmo, G.M., Henriques, C.M., Coelho, G.E., Araújo de França, G.V., Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015. MMWR Morb. Mortal. Wkly. Rep. 65 (2016), 242–247.
42. Kostyuchenko, V.A., Lim, E.X., Zhang, S., Fibriansah, G., Ng, T.S., Ooi, J.S., Shi, J., Lok, S.M., Structure of the thermally stable Zika virus. Nature 533 (2016), 425–428.
43. Kuhn, R.J., Zhang, W., Rossmann, M.G., Pletnev, S.V., Corver, J., Lenches, E., Jones, C.T., Mukhopadhyay, S., Chipman, P.R., Strauss, E.G., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 (2002), 717–725.
44. Lai, C.Y., Williams, K.L., Wu, Y.C., Knight, S., Balmaseda, A., Harris, E., Wang, W.K., Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl. Trop. Dis., 7, 2013, e2451.
45. Lanciotti, R.S., Kosoy, O.L., Laven, J.J., Velez, J.O., Lambert, A.J., Johnson, A.J., Stanfield, S.M., Duffy, M.R., Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14 (2008), 1232–1239.
46. Larocca, R.A., Abbink, P., Peron, J.P., Zanotto, P.M., Iampietro, M.J., Badamchi-Zadeh, A., Boyd, M., Ng'ang’a, D., Kirilova, M., Nityanandam, R., et al. Vaccine protection against Zika virus from Brazil. Nature 536 (2016), 474–478.
47. Lazear, H.M., Govero, J., Smith, A.M., Platt, D.J., Fernandez, E., Miner, J.J., Diamond, M.S., A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19 (2016), 720–730.
48. Lednicky, J., Beau De Rochars, V.M., El Badry, M., Loeb, J., Telisma, T., Chavannes, S., Anilis, G., Cella, E., Ciccozzi, M., Rashid, M., et al. Zika virus outbreak in haiti in 2014: molecular and clinical data. PLoS Negl. Trop. Dis., 10, 2016, e0004687.
49. Lessler, J., Chaisson, L.H., Kucirka, L.M., Bi, Q., Grantz, K., Salje, H., Carcelen, A.C., Ott, C.T., Sheffield, J.S., Ferguson, N.M., et al. Assessing the global threat from Zika virus. Science, 353, 2016, aaf8160.
50. Li, L., Lok, S.M., Yu, I.M., Zhang, Y., Kuhn, R.J., Chen, J., Rossmann, M.G., The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319 (2008), 1830–1834.
51. Lorenz, I.C., Allison, S.L., Heinz, F.X., Helenius, A., Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J. Virol. 76 (2002), 5480–5491.
52. Martin, J.E., Pierson, T.C., Hubka, S., Rucker, S., Gordon, I.J., Enama, M.E., Andrews, C.A., Xu, Q., Davis, B.S., Nason, M., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196 (2007), 1732–1740.
53. Mongkolsapaya, J., Dejnirattisai, W., Xu, X.N., Vasanawathana, S., Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S., Duangchinda, T., Dong, T., Rowland-Jones, S., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9 (2003), 921–927.
54. Mukhopadhyay, S., Kim, B.S., Chipman, P.R., Rossmann, M.G., Kuhn, R.J., Structure of West Nile virus. Science, 302, 2003, 248.
55. Muller, D.A., Young, P.R., The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 98 (2013), 192–208.
56. Musso, D., Roche, C., Robin, E., Nhan, T., Teissier, A., Cao-Lormeau, V.M., Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21 (2015), 359–361.
57. Mysorekar, I.U., Diamond, M.S., Modeling zika virus infection in pregnancy. N. Engl. J. Med. 375 (2016), 481–484.
58. Nowakowski, T.J., Pollen, A.A., Di Lullo, E., Sandoval-Espinosa, C., Bershteyn, M., Kriegstein, A.R., Expression Analysis Highlights AXL as a Candidate Zika Virus Entry Receptor in Neural Stem Cells. Cell Stem Cell 18 (2016), 591–596.
59. Nybakken, G.E., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H., Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 (2005), 764–769.
60. Pierson, T.C., Diamond, M.S., Degrees of maturity: the complex structure and biology of flaviviruses. Curr. Opin. Virol. 2 (2012), 168–175.
61. Pierson, T.C., Diamond, M.S., Vaccine development as a means to control dengue virus pathogenesis: do we know enough?. Annu. Rev. Virol. 1 (2014), 375–398.
62. Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, D.H., Diamond, M.S., The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1 (2007), 135–145.
63. Priyamvada, L., Quicke, K.M., Hudson, W.H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M.J., Wilson, P.C., et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. USA 113 (2016), 7852–7857.
64. Quicke, K.M., Suthar, M.S., The innate immune playbook for restricting West Nile virus infection. Viruses 5 (2013), 2643–2658.
65. Quicke, K.M., Bowen, J.R., Johnson, E.L., McDonald, C.E., Ma, H., O'Neal, J.T., Rajakumar, A., Wrammert, J., Rimawi, B.H., Pulendran, B., et al. Zika Virus Infects Human Placental Macrophages. Cell Host Microbe 20 (2016), 83–90.
66. Rasmussen, S.A., Jamieson, D.J., Honein, M.A., Petersen, L.R., Zika Virus and Birth Defects-Reviewing the Evidence for Causality. N. Engl. J. Med. 374 (2016), 1981–1987.
67. Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C., The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 (1995), 291–298.
68. Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., Duquerroy, S., Vaney, M.C., Kikuti, C.M., Navarro Sanchez, M.E., Dejnirattisai, W., Wongwiwat, W., Haouz, A., et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520 (2015), 109–113.
69. Sabin, A.B., Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1 (1952), 30–50.
70. Savidis, G., Perreira, J.M., Portmann, J.M., Meraner, P., Guo, Z., Green, S., Brass, A.L., The IFITMs Inhibit Zika Virus Replication. Cell Rep. 15 (2016), 2323–2330.
71. Screaton, G., Mongkolsapaya, J., Yacoub, S., Roberts, C., New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15 (2015), 745–759.
72. Shrestha, B., Diamond, M.S., Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 78 (2004), 8312–8321.
73. Sirivichayakul, C., Barranco-Santana, E.A., Esquilin-Rivera, I., Oh, H.M., Raanan, M., Sariol, C.A., Shek, L.P., Simasathien, S., Smith, M.K., Velez, I.D., et al. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J. Infect. Dis. 213 (2016), 1562–1572.
74. Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., Kuhn, R.J., The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352 (2016), 467–470.
75. Stettler, K., Beltramello, M., Espinosa, D.A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353 (2016), 823–826.
76. Swanstrom, J.A., Plante, J.A., Plante, K.S., Young, E.F., McGowan, E., Gallichotte, E.N., Widman, D.G., Heise, M.T., de Silva, A.M., Baric, R.S., Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against zika virus. MBio, 7, 2016 e01123–16.
77. Tabata, T., Petitt, M., Puerta-Guardo, H., Michlmayr, D., Wang, C., Fang-Hoover, J., Harris, E., Pereira, L., Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 20 (2016), 155–166.
78. Ventura, C.V., Maia, M., Bravo-Filho, V., Góis, A.L., Belfort, R. Jr., Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet, 387, 2016, 228.
79. Wang, T., Welte, T., Role of natural killer and Gamma-delta T cells in West Nile virus infection. Viruses 5 (2013), 2298–2310.
80. Weiskopf, D., Angelo, M.A., de Azeredo, E.L., Sidney, J., Greenbaum, J.A., Fernando, A.N., Broadwater, A., Kolla, R.V., De Silva, A.D., de Silva, A.M., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. USA 110 (2013), E2046–E2053.
81. Weiskopf, D., Bangs, D.J., Sidney, J., Kolla, R.V., De Silva, A.D., de Silva, A.M., Crotty, S., Peters, B., Sette, A., Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. USA 112 (2015), E4256–E4263.
82. Wikan, N., Smith, D.R., Zika virus: history of a newly emerging arbovirus. Lancet Infect. Dis. 16 (2016), e119–e126.
83. Zanluca, C., Melo, V.C., Mosimann, A.L., Santos, G.I., Santos, C.N., Luz, K., First report of autochthonous transmission of Zika virus in Brazil. Mem. Inst. Oswaldo Cruz 110 (2015), 569–572.
84. Zhang, X., Ge, P., Yu, X., Brannan, J.M., Bi, G., Zhang, Q., Schein, S., Zhou, Z.H., Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat. Struct. Mol. Biol. 20 (2013), 105–110.
85. Zhao, H., Fernandez, E., Dowd, K.A., Speer, S.D., Platt, D.J., Gorman, M.J., Govero, J., Nelson, C.A., Pierson, T.C., Diamond, M.S., Fremont, D.H., Structural basis of zika virus-specific antibody protection. Cell 166 (2016), 1016–1027.